Plain-English translation of NCT04807673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two different ways to prepare your body for esophageal cancer surgery. One group will receive — a medication that helps your immune system fight cancer — combined with standard chemotherapy drugs. The other group will receive radiation therapy combined with chemotherapy. Both approaches are designed to shrink the cancer before your surgeon removes the affected part of your esophagus.
Radiation therapy, while effective, causes serious side effects that many patients find difficult to tolerate. Researchers want to see if this newer immunotherapy medication combined with chemotherapy alone might work just as well or even better, while being easier for patients to handle.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. You'll receive either three cycles of chemotherapy plus the new immunotherapy medication (given intravenously every three weeks), or five weeks of radiation therapy combined with weekly chemotherapy. After completing this treatment, you'll have surgery to remove the affected part of your esophagus. If you're in the medication group, you'll continue receiving the immunotherapy for about one year after surgery. Throughout the trial, you'll have regular clinic visits, blood tests, and scans to monitor how you're responding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China